Future concepts in bronchodilation for COPD: dual-

Most patients with COPD are recommended to initiate maintenance therapy with a single long-acting bronchodilator, such as a long-acting muscarinic antagonist or long-acting β

Informations de copyright

Copyright ©The authors 2021.

Déclaration de conflit d'intérêts

Conflict of interest: D. Singh reports other funding from GlaxoSmithKline and non-financial support from GlaxoSmithKline, during the conduct of the study. He reports personal fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici S.p.A., Cipla, Genentech, GlaxoSmithKline, Glenmark, Gossamerbio, Novartis, Pfizer Inc., Pulmatrix, Teva, Theravance Biopharma, Menarini and Verona Pharma, outside the submitted work. Conflict of interest: J.F. Donohue reports other funding from GlaxoSmithKline and non-financial support from GlaxoSmithKline, during the conduct of the study. He reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, GlaxoSmithKline, Mylan, Theravance and Sunovion, and other funding from AstraZeneca, Avillion, Merck, CSA and INSMED, outside the submitted work. Conflict of interest: I.H. Boucot reports other funding from GlaxoSmithKline and non-financial support from GlaxoSmithKline, during the conduct of the study. She reports personal fees from GlaxoSmithKline and other funding from GlaxoSmithKline, outside the submitted work. Conflict of interest: N.C. Barnes reports other funding from GlaxoSmithKline and non-financial support from GlaxoSmithKline, during the conduct of the study. He reports personal fees from GlaxoSmithKline and other funding from GlaxoSmithKline, outside the submitted work. Conflict of interest: C. Compton reports other funding from GlaxoSmithKline and non-financial support from GlaxoSmithKline, during the conduct of the study. He reports personal fees from GlaxoSmithKline and other funding from GlaxoSmithKline, outside the submitted work. Conflict of interest: F.J. Martinez reports other funding from GlaxoSmithKline, non-financial support from GlaxoSmithKline, and personal fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim and Raziel, during the conduct of the study. He reports personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Miller Communications, National Society for Continuing Education, PeerView Communications, Chiesi, Sunovion, American Thoracic Society, Rockpointe, Csl Behring, Sanofi/Regeneron, Teva, Canadian Respiratory Network, Physicians Education Resource; non-financial support from ProterrixBio, Gilead, Nitto, Zambon; personal fees, non-financial support and other from Genentech; personal fees from MD Magazine, Methodist Hospital Brooklyn, New York University, UpToDate, WebMD/MedScape, Patara/Respivant, CME Outfitters, Integritas, DevPro, Dartmouth University, IQVIA, Projects in Knowledge, Vindico, Academy for Continuing Healthcare Learning; personal fees and other from Bayer; other from Afferent/Merck, Biogen, Veracyte, Prometic, Bridge Biotherapeutics, Gala, twoXAR, AbbVie; and grants from NIH, Rare Disease Healthcare Communications, ProMedior/Roche, outside the submitted work.